The estimated Net Worth of Louis W Sullivan is at least $16.4 Million dollars as of 3 May 2024. Louis Sullivan owns over 5,160 units of United Therapeutics Corp stock worth over $6,307,582 and over the last 21 years he sold UTHR stock worth over $9,618,140. In addition, he makes $441,740 as Independent Director at United Therapeutics Corp.
Louis has made over 58 trades of the United Therapeutics Corp stock since 2004, according to the Form 4 filled with the SEC. Most recently he exercised 5,160 units of UTHR stock worth $617,962 on 3 May 2024.
The largest trade he's ever made was exercising 47,631 units of United Therapeutics Corp stock on 12 May 2016 worth over $478,692. On average, Louis trades about 4,156 units every 50 days since 2003. As of 3 May 2024 he still owns at least 18,220 units of United Therapeutics Corp stock.
You can see the complete history of Louis Sullivan stock trades at the bottom of the page.
The Hon. Dr. Louis W. Sullivan M.D. serves as Independent Director of the Company. Dr. Sullivan was the founding President of Morehouse School of Medicine, from 1981 to 1989, served as President again from 1993 to 2002, and has served as President Emeritus since 2002. Dr. Sullivan was also one of the founders and served as Chairman of Medical Education for South African Blacks, Inc., a member of the National Executive Council for the Boy Scouts of America, and a member of the Board of Trustees of Little League of America. Dr. Sullivan served as Secretary of the U.S. Department of Health and Human Services from 1989 to 1993. He is a physician certified in internal medicine with a subspecialty certification in hematology. Dr. Sullivan currently serves on the board of directors of Emergent BioSolutions, Inc. (since 2005), a publicly-traded company. He also serves as Co-Chair of the Henry Schein Cares Foundation. Dr. Sullivan previously served on the boards of directors of a wide range of public companies, including General Motors Company, BioSante Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Cigna Corporation, 3M Company, Henry Schein, Inc., Household International (now HSBC), Equifax and Georgia Pacific Corporation. He has served as a United Therapeutics director since 2002.
As the Independent Director of United Therapeutics Corp, the total compensation of Louis Sullivan at United Therapeutics Corp is $441,740. There are 13 executives at United Therapeutics Corp getting paid more, with Martine Rothblatt having the highest compensation of $15,627,500.
Louis Sullivan is 86, he's been the Independent Director of United Therapeutics Corp since 2002. There are no older and 20 younger executives at United Therapeutics Corp.
Louis's mailing address filed with the SEC is C/O UNITED THERAPEUTICS CORPORATION, 1000 SPRING STREET, SILVER SPRING, MD, 20910.
Over the last 20 years, insiders at United Therapeutics Corp have traded over $68,910,395 worth of United Therapeutics Corp stock and bought 229,703 units worth $13,655,671 . The most active insiders traders include Martine A Rothblatt, David Zaccardelli, and Roger Jeffs. On average, United Therapeutics Corp executives and independent directors trade stock every 3 days with the average trade being worth of $2,310,818. The most recent stock trade was executed by James Edgemond on 9 September 2024, trading 8,332 units of UTHR stock currently worth $991,341.
united therapeutics corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. we currently have five approved products on the market, and a long-term mission of providing an unlimited supply of transplantable organs for those who need them! our employees can be found collaborating across the united states, europe and asia. as a group, we are relentless in our pursuit of “medicines for life” and continue to research and develop treatments for cardiovascular and pulmonary diseases, pediatric cancers, and other orphan diseases. #weareunitherians
United Therapeutics Corp executives and other stock owners filed with the SEC include: